Critical Survey: Vascular Biogenics (VBLT) vs. Gemphire Therapeutics (GEMP)
Vascular Biogenics (NASDAQ: VBLT) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap bio therapeutic drugs companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.
Volatility and Risk
Vascular Biogenics has a beta of -3.1, suggesting that its share price is 410% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 3.59, suggesting that its share price is 259% more volatile than the S&P 500.
Insider & Institutional Ownership
11.2% of Vascular Biogenics shares are held by institutional investors. Comparatively, 32.1% of Gemphire Therapeutics shares are held by institutional investors. 34.0% of Gemphire Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Vascular Biogenics and Gemphire Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Vascular Biogenics and Gemphire Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vascular Biogenics currently has a consensus price target of $14.75, indicating a potential upside of 139.84%. Gemphire Therapeutics has a consensus price target of $24.40, indicating a potential upside of 154.17%. Given Gemphire Therapeutics’ higher possible upside, analysts clearly believe Gemphire Therapeutics is more favorable than Vascular Biogenics.
Valuation & Earnings
This table compares Vascular Biogenics and Gemphire Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Vascular Biogenics||N/A||N/A||-$16.00 million||($0.66)||-9.32|
|Gemphire Therapeutics||N/A||N/A||-$14.58 million||($3.12)||-3.08|
Vascular Biogenics is trading at a lower price-to-earnings ratio than Gemphire Therapeutics, indicating that it is currently the more affordable of the two stocks.
Gemphire Therapeutics beats Vascular Biogenics on 6 of the 9 factors compared between the two stocks.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.